| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000014562 |
| Receipt No. | R000016756 |
| Scientific Title | Low-energy extracorporeal cardiac shock wave therapy in patients with acute myocardial infarction |
| Date of disclosure of the study information | 2014/07/15 |
| Last modified on | 2020/03/07 (Ver. 8) |
| Basic information | ||
| Public title | Low-energy extracorporeal cardiac shock wave therapy in patients with acute myocardial infarction | |
| Acronym | Shock wave therapy for AMI | |
| Scientific Title | Low-energy extracorporeal cardiac shock wave therapy in patients with acute myocardial infarction | |
| Scientific Title:Acronym | Shock wave therapy for AMI | |
| Region |
|
|
| Condition | ||
| Condition | Acute myocardial infarction | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To suppress left ventricular (LV) remodeling after acute myocardial infarction (AMI) |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | LV volume and LV ejection fraction at 6 months and 12 months after AMI |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Low-energy extracorporeal cardiac shock wave therapy (3 times in the first week. 30 or less spots around infarcted area, 200 shots/spot each time) | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) 20-79 year-old men, 20-74-year-old women.
2) Reperfusion therapy is succeeded with no distal emboli. 3) Therapy can be started within 72 hours after the onset of AMI. 4) The peak CK in serum is 4000 U/L or less. |
|||
| Key exclusion criteria | 1) Patients with cardiogenic shock or congestive heart failure (who require continuous infusion of cardiovascular agents such as inotropic agents or vasodilators).
2) Patients with severe arrhythmia requiring a cardioversion procedure after PCI. 3) Broad anterior AMI. 4) Patients whose target area cannot be observed with echocardiography. 5) Post-breast augmentation surgery with silicon pad. 6) Intracardiac thrombus. 7) Patients who have malignancy or who have undergone surgery because of malignancy within the past five years. |
|||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Tohoku University Graduate School of Medicine | ||||||
| Division name | Department of Cardiovascular Medicine | ||||||
| Zip code | 980-5874 | ||||||
| Address | 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574 | ||||||
| TEL | 022-717-7153 | ||||||
| cswt@cardio.med.tohoku.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Tohoku University Graduate School of Medicine | ||||||
| Division name | Department of Cardiovascular Medicine | ||||||
| Zip code | 980-8574 | ||||||
| Address | 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574 | ||||||
| TEL | 022-717-7153 | ||||||
| Homepage URL | http://www.cardio.med.tohoku.ac.jp/shockwave/index.html | ||||||
| cswt@cardio.med.tohoku.ac.jp | |||||||
| Sponsor | |
| Institute | Tohoku University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japanese Ministry of Health, Labor, and Welfare |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Clinical Research, Innovation and Education Center, Tohoku University Hospital |
| Address | 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574 |
| Tel | 022-717-7122 |
| cswt@cardio.med.tohoku.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | https://www.ncbi.nlm.nih.gov/pubmed/29068804 |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | https://www.ncbi.nlm.nih.gov/pubmed/29068804 | ||||||
| Number of participants that the trial has enrolled | 17 | ||||||
| Results | At 6 and 12 months after AMI, LV function as assessed by MRI showed no signs of deleterious LV remodeling. When we compared the SW-treated group with the historical AMI controls at 6 months after AMI, LV ejection fraction was significantly higher in the SW-treated group (N=7) than in the historical control group (N=25) by echocardiography. LV end-diastolic dimension also tended to be smaller in the SW than in the control group. |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | Seventeen patients with AMI who successfully underwent primary PCI (peak-creatine kinase<4000U/l) were treated with the SW therapy. |
||||||
| Participant flow | Registered in one institute. |
||||||
| Adverse events | There were no procedure-related complications or adverse effects. |
||||||
| Outcome measures | LV function as assessed by MRI. |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016756 |